CN115531411B - 一种具备ct成像和治疗双重作用的药物及其制备方法和应用 - Google Patents
一种具备ct成像和治疗双重作用的药物及其制备方法和应用 Download PDFInfo
- Publication number
- CN115531411B CN115531411B CN202211136013.2A CN202211136013A CN115531411B CN 115531411 B CN115531411 B CN 115531411B CN 202211136013 A CN202211136013 A CN 202211136013A CN 115531411 B CN115531411 B CN 115531411B
- Authority
- CN
- China
- Prior art keywords
- medicine
- deionized water
- imaging
- centrifuging
- chondroitin sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 238000013170 computed tomography imaging Methods 0.000 title claims abstract description 24
- 238000011282 treatment Methods 0.000 title claims abstract description 24
- 230000009977 dual effect Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 title abstract description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 29
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical group FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 23
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 23
- 229910052715 tantalum Inorganic materials 0.000 claims abstract description 12
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000008367 deionised water Substances 0.000 claims description 22
- 229910021641 deionized water Inorganic materials 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 15
- 238000005406 washing Methods 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000006116 polymerization reaction Methods 0.000 claims description 6
- 239000002356 single layer Substances 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 3
- 239000010410 layer Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 230000000379 polymerizing effect Effects 0.000 claims description 2
- -1 polytetrafluoroethylene Polymers 0.000 claims description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract description 21
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 11
- 230000002757 inflammatory effect Effects 0.000 abstract description 6
- 230000003902 lesion Effects 0.000 abstract description 6
- 238000009826 distribution Methods 0.000 abstract description 5
- 230000009885 systemic effect Effects 0.000 abstract description 4
- 150000001336 alkenes Chemical class 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 239000002872 contrast media Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- QPJSUIGXIBEQAC-UHFFFAOYSA-N n-(2,4-dichloro-5-propan-2-yloxyphenyl)acetamide Chemical compound CC(C)OC1=CC(NC(C)=O)=C(Cl)C=C1Cl QPJSUIGXIBEQAC-UHFFFAOYSA-N 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229960004537 ioversol Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052757 nitrogen Chemical group 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/90—Carbides
- C01B32/914—Carbides of single elements
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/001—Macromolecular compounds containing organic and inorganic sequences, e.g. organic polymers grafted onto silica
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/20—Two-dimensional structures
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/01—Particle morphology depicted by an image
- C01P2004/04—Particle morphology depicted by an image obtained by TEM, STEM, STM or AFM
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/51—Particles with a specific particle size distribution
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/40—Electric properties
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明涉及一种具备CT成像和治疗双重作用的药物及其制备方法和应用,涉及药物制备技术领域。本发明的药物,其为片状钽迈克烯(Ta2C),所述片状钽迈克烯上修饰有硫酸软骨素(CS),表达式为Ta2C‑CS。本发明的药物的制备方法包括:步骤(1)、制备片状Ta2C;步骤(2)、采用硫酸软骨素修饰步骤1制备的片状Ta2C,获得Ta2C‑CS。本发明还提供的所述药物在制备治疗炎症性肠病的药物上的应用。本发明提供的药物,能够保证药物在复杂胃肠道环境中稳定性的前提下,有效靶向富集于IBD患者炎性病变部位同时发挥CT成像和治疗双重作用,同时避免全身分布保证安全性。
Description
技术领域
本发明涉及药物制备技术领域,具体涉及一种具备CT成像和治疗双重作用的药物及其制备方法和应用。
背景技术
炎症性肠病(Inflammatory Bowel Disease,IBD)是一种胃肠道非传染性慢性炎症,主要包括克罗恩病(Crohn’s Disease,CD)、溃疡性结肠炎(Ulcerative Colitis,UC),多发于中青年患者中,病程迁延不愈,严重影响患者生活工作质量,给个人、家庭和社会带来极大的负担。
IBD的临床诊断主要依据病理学,但是特异性较差。IBD患者需要终生复查,评估病情,但临床上常用的CT扫描对IBD的诊断价值有限,碘增强对比剂对IBD无特异性,应用价值不大;而消化道内镜的反复应用,患者会遭受较大的痛苦。
IBD不仅诊断困难而且无法治愈,临床上常用的药物主要通过抗炎、免疫抑制等改善患者症状,但它们靶向性不强、效果不一并且往往伴随着严重的不良反应。IBD患者病变部位会有大量活性氧成分(ROS)生成,进一步加剧免疫炎症失调是IBD发生发展的主要原因之一。局部清除ROS对IBD患者可发挥良好的治疗作用。因此,开发一种IBD特异性的CT成像对比剂同时具备ROS清除能力,用于IBD患者的诊断、病情评估和治疗意义重大。
发明内容
有鉴于此,本发明要解决的技术问题是提供一种具备CT成像和治疗双重作用的药物及其制备方法和应用。本发明提供的药物,能够保证药物在复杂胃肠道环境中稳定性的前提下,有效靶向富集于IBD患者炎性病变部位同时发挥CT成像和治疗双重作用,同时避免全身分布保证安全性。
为了解决上述技术问题,本发明的技术方案具体如下:
本发明提供一种具备CT成像和治疗双重作用的药物,其为片状钽迈克烯(Ta2C),所述片状钽迈克烯上修饰有硫酸软骨素(CS),表达式为Ta2C-CS。
本发明还提供一种具备CT成像和治疗双重作用的药物的制备方法,包括以下步骤:
步骤(1)、制备片状Ta2C;
步骤(2)、采用硫酸软骨素修饰步骤1制备的片状Ta2C,获得具备CT成像和治疗双重作用的药物Ta2C-CS。
在上述技术方案中,优选的是,步骤(1)包括以下步骤:
采用氢氟酸蚀刻Ta2AlC后,超声剥离合成单层片状Ta2C。
在上述技术方案中,进一步优选的是,步骤(1)具体包括以下步骤:
通过将49%的氢氟酸(HF)溶液以去离子水稀释成10%浓度的HF溶液,缓慢加入装有适量MAX相Ta2AlC粉末的聚四氟乙烯容器中,室温搅拌反应24h,然后用去离子水洗涤、离心和倾析直到pH达到为6左右,得到多层片状Ta2C,将其继续分散在去离子水中,超声剥离48h,然后用去离子水洗涤、离心,重复三次得到单层片状Ta2C。
在上述技术方案中,优选的是,步骤(2)包括以下步骤:
取步骤(1)所制备的片状Ta2C分散在去离子水中,加入硫酸软骨素,超声下聚合,聚合结束后通过离心分离,然后用去离子水洗涤离心,得到具备CT成像和治疗双重作用的药物Ta2C-CS。
在上述技术方案中,进一步优选的是,步骤(2)中所述片状Ta2C与硫酸软骨素的质量比为1:10。
在上述技术方案中,进一步优选的是,步骤(2)中超声下聚合的时间为48小时。
在上述技术方案中,进一步优选的是,步骤(2)中去离子水洗涤离心具体为:去离子水洗涤后于11000rpm下离心10min,重复次数为三次。
在上述技术方案中,进一步优选的是,步骤(2)中离心分离具体为将聚合结束后的溶液首先于1000rmp离心1min后取上层溶液,接着于11000rpm下离心10min,获得Ta2C-CS沉淀。
本发明还提供一种具备CT成像和治疗双重作用的药物在制备治疗炎症性肠病的药物上的应用。
本发明的有益效果是:
本发明提供的具备CT成像和治疗双重作用的药物(Ta2C-CS),具备以下优势:
(1)优异的CT成像能力:相比临床上常用的碘增强对比剂,钽的X射线衰减能力较碘更强。
(2)稳定性:在胃肠道环境(强酸和弱碱)能够保持结构和功能稳定。
(3)安全性:生物相容性好,同时不被肠道吸收不发生全身分布。
(4)靶向性:Ta2C-CS带负电,可与肠道炎症病灶正电性蛋白结合(正常上皮负电性);同时CS可与炎症病灶大量表达CD44结合。
(5)有效性:Ta2C-CS具备高效的ROS清除能力和炎症免疫调节能力。
本发明提供的具备CT成像和治疗双重作用的药物(Ta2C-CS)的制备方法,采用生物兼容性极佳的钽迈克烯(Ta2C)作为主要合成原料,通过氢氟酸(HF)蚀刻Ta2AlC获得片状Ta2C,通过硫酸软骨素(CS)对Ta2C进行修饰增加其溶液稳定性和表面负电荷,制备得到的Ta2C-CS具有如上优势。并且本发明的方法所采用的原料价格低廉易得、合成方法简单,是一种简单、绿色的合成方法。
本发明提供的具备CT成像和治疗双重作用的药物可通过口服靶向诊断和治疗IBD,并能够保证药物在复杂胃肠道环境中稳定性的前提下,有效靶向富集于IBD患者炎性病变部位同时发挥CT成像和治疗双重作用,同时避免全身分布保证安全性。
附图说明
下面结合附图和具体实施方式对本发明作进一步详细说明。
图1为实施例制备的(A)Ta2C-CS的TEM图,(B)Ta2C和Ta2C-CS电位表征,(C)Ta2C-CS粒径分布图。
图2为实施例制备的Ta2C-CS的安全性考察图,其中体外(A)和体内(B)。
图3为实施例制备的Ta2C-CS的稳定性考察结果图,其中(A-B)分别为胃肠道模拟液(GFS)处理前后的TEM和Zeta电位结果图,(C-E)分别为处理前后Ta2C-CS对O2 ·-,H2O2,OH·-,的清除能力检测。
图4为实施例制备的Ta2C-CS的CT成像效果图,其中(A-B)Ta2C-CS和碘佛醇的CT对比信号分析结果,(C)不同分组小鼠给予不同对比剂、不同时间点CT值分析结果。
图5为口服Ta2C-CS 24小时后的成像结果及CT值分析图,其中(A-B)分别为空白对照和口服Ta2C-CS 24小时后的CT整体成像和解剖成像结果图,(C)为CT值分析结果图。
图6为Ta2C-CS的靶向性考察结果图,其中Ta2C-CS(A)以及荧光素标记的Ta2C-CS(B)均富集于IBD肠道病变部位(A,黑色箭头)。
图7为Ta2C-CS的有效性考察结果图,其中(A)体重监测结果,(B)疾病活动指数(DAI)结果,(C)结肠长度分析,(D)结肠组织切片染色结果。
具体实施方式
以下实施例所用的硫酸软骨素、及其他试剂均为商品化产品。
实施例
(1)片状Ta2C的制备:
通过将49%的氢氟酸(HF)溶液以去离子水稀释成10%浓度的HF溶液20mL,缓慢加入装有1g MAX相Ta2AlC粉末(MAX相Ta2AlC粉末中M代表早期过渡金属元素,A代表第13或14族元素,X代表碳或氮元素)的聚四氟乙烯容器中,室温磁性搅拌反应24h。然后用去离子水洗涤、离心(11000rpm 10min)和倾析直到pH达到约为6,得到多层片状Ta2C,将其继续分散在去离子水中,超声剥离48h,然后用去离子水洗涤、离心(11000rpm 10min),重复三次得到单层片状Ta2C。
(2)硫酸软骨素修饰Ta2C制备:
取(1)中片状Ta2C烘干称重,按片状Ta2C与硫酸软骨素质量比1:10加入硫酸软骨素,混合于去离子水中,室温下超声48小时,硫酸软骨素结合于Ta2C表面后,低速离心(1000rmp 1min)后取上层溶液,高速离心(11000rpm,10min)获得Ta2C-CS沉淀,去离子水洗涤、离心(11000rpm 10min),重复三次得到单层Ta2C-CS药物。所得Ta2C-CS,为片状结构,带负电荷,平均粒径为310.3nm参见图1。
(3)体内外实验验证Ta2C-CS药物的治疗效果
体外安全性:不同浓度Ta2C-CS(10、20、40、80、160、320μg/mL)分别与HT29共孵育48小时,MTT检测细胞活性。
体内安全性:分别给于8周雄性小鼠H2O和Ta2C-CS灌胃(300mg/Kg,隔天一次,共四次,每组6只),每天监测小鼠体重变化。
对酸稳定性:给于Ta2C-CS酸处理(pH=1.5)4小时后碱处理(pH=8)1小时,通过TEM和zeta电位检测对处理前后Ta2C-CS进行表征,并对ROS(O2 ·-,H2O2,OH·-)清除能力进行检测。
具体检测过程:1.将不同浓度(0,12.5,25,50,100μg/mL)的Ta2C-CS与H2O2混合后避光反应12小时,紫外分光光度法检测H2O2吸光度变化,反映H2O2清除效率。2.反应体系(3mL)配制:TMB(0.5M)、硫酸亚铁(2.5mM),H2O2(1mM)和不同浓度(0,25,50,100,200μg/mL)的Ta2C-CS混合,反应4min,紫外分光光度法测定650nm波长处吸光度变化情况,反映OH·-清除效果。3.反应体系(3mL)配制:核黄素(20μM)、甲硫氨酸(0.01M),NBT(0.01M)PBS(0.01M,pH7.4)和不同浓度(0,50,100,200,300μg/mL)的Ta2C-CS。紫外照射反应5min,紫外分光光度法测定560nm波长处吸光度变化情况,反映O2 ·-清除效果。
靶向性检测:给于8周的雄性小鼠自由饮用3%DSS溶液7天,建立小鼠IBD模型。给于健康小鼠和模型小鼠Ta2C-CS(以及荧光素标记的Ta2C-CS)灌胃24小时后取结肠组织切片进行电镜观察和结肠荧光强度检测(每组3只)。
有效性检测:给于8周的雄性小鼠自由饮用3%DSS溶液7天,建立小时IBD模型,每组6只小鼠。分别给于不同药物(隔天一次,共四次)的CS(30mg/Kg),Ta2C(30mg/Kg),Ta2C-CS(30mg/Kg),5-ASA(30mg/Kg),监测小鼠体重变化,症状。第10天处死小鼠,取结肠组织染色观察。
检测结果如下:
从药物的安全性角度考虑,钽元素具有良好的生物兼容性,在临床上被广泛用于医疗器材和植入材料;而且硫酸软骨素广泛存在人体细胞外基质和细胞表面等,也被临床用于疾病治疗,因此Ta2C-CS理论上是安全的。对其生物兼容性进行考察,通过细胞毒性试验(MTT),发现其对细胞的生长、发育和复制均无不良影响,在320μg/mL的高浓度条件下,细胞的存活不受影响;体内实验表明,在高剂量下(300mg/Kg体重)对小鼠无明显毒副作用(参见图2)。以上实验数据说明,Ta2C-CS具有非常良好的生物兼容性。
从药物稳定性角度考虑,钽元素对酸碱稳定,因此对胃肠道环境稳定。通过胃肠道模拟液(GFS)处理Ta2C-CS后,对其结构和功能稳定性进行检测,结果表明处理前后其结构和功能稳定性良好(参见图3)。
从CT成像效果的角度进行评价,Ta2C-CS较临床对比剂碘佛醇的X线衰减能力更强(参见图4)。小鼠体内实验结果表明,口服Ta2C-CS 24小时后,其可有效富集于IBD小鼠肠道炎症部位,CT成像结果清晰可辨(参见图5)。
从药物的靶向性角度考虑,Ta2C-CS可通过静电相互作用和受体配体结合靶向富集IBD患者肠道炎症病灶。通过对组织切片进行电镜观察,同时对Ta2C-CS进行荧光素标记,检测肠道组织荧光水平,结果均表明Ta2C-CS能靶向富集病变部位(参见图6)。
从药物的有效性角度考虑,Ta2C-CS对IBD小鼠模型具有显著治疗效果,改善症状,恢复肠道正常结构(参见图7)。
显然,上述实施例仅仅是为清楚地说明所作的举例,而并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (5)
1.一种具备CT成像和治疗双重作用的治疗炎症性肠病的药物,其特征在于,其为片状钽迈克烯(Ta2C),所述片状钽迈克烯上修饰有硫酸软骨素(CS),表达式为Ta2C-CS;
所述药物的制备方法,包括以下步骤:
步骤(1)、制备片状Ta2C;
通过将49%的氢氟酸溶液以去离子水稀释成10%浓度的HF溶液,加入装有MAX相Ta2AlC粉末的聚四氟乙烯容器中,室温搅拌反应24h,然后用去离子水洗涤、离心和倾析直到pH达到6,得到多层片状Ta2C,将其继续分散在去离子水中,超声剥离48h,然后用去离子水洗涤、离心,重复三次得到单层片状Ta2C;
步骤(2)、采用硫酸软骨素修饰步骤1制备的片状Ta2C;
取步骤(1)所制备的片状Ta2C分散在去离子水中,加入硫酸软骨素,超声下聚合,聚合结束后通过离心分离,然后用去离子水洗涤离心,得到具备CT成像和治疗双重作用的治疗炎症性肠病的药物Ta2C-CS;
步骤(2)中所述片状Ta2C与硫酸软骨素的质量比为1:10。
2.根据权利要求1所述的药物,其特征在于,步骤(2)中超声下聚合的时间为48小时。
3.根据权利要求1所述的药物,其特征在于,步骤(2)中去离子水洗涤离心具体为:去离子水洗涤后于11000rpm下离心10min,重复次数为三次。
4.根据权利要求1所述的药物,其特征在于,步骤(2)中离心分离具体为将聚合结束后的溶液首先于1000rmp离心1min后取上层溶液,接着于11000rpm下离心10min,获得Ta2C-CS沉淀。
5.一种权利要求1所述的具备CT成像和治疗双重作用的治疗炎症性肠病的药物在制备治疗炎症性肠病的药物上的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211136013.2A CN115531411B (zh) | 2022-09-19 | 2022-09-19 | 一种具备ct成像和治疗双重作用的药物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211136013.2A CN115531411B (zh) | 2022-09-19 | 2022-09-19 | 一种具备ct成像和治疗双重作用的药物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115531411A CN115531411A (zh) | 2022-12-30 |
CN115531411B true CN115531411B (zh) | 2023-09-01 |
Family
ID=84727920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211136013.2A Active CN115531411B (zh) | 2022-09-19 | 2022-09-19 | 一种具备ct成像和治疗双重作用的药物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115531411B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023204279A1 (ja) * | 2022-04-21 | 2023-10-26 | 株式会社村田製作所 | 吸着材、吸着シート、分離膜、人工透析機器および製造方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111184908A (zh) * | 2020-01-20 | 2020-05-22 | 广东工业大学 | 一种抗菌的压电Mxene复合材料及其应用 |
-
2022
- 2022-09-19 CN CN202211136013.2A patent/CN115531411B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111184908A (zh) * | 2020-01-20 | 2020-05-22 | 广东工业大学 | 一种抗菌的压电Mxene复合材料及其应用 |
Non-Patent Citations (1)
Title |
---|
Polysaccharide/Ti3C2Tx MXene adhesive hydrogels with self-healing ability for multifunctional and sensitive sensors;Yang He等;《Carbohydrate Polymers》;第291卷;第1-9页 * |
Also Published As
Publication number | Publication date |
---|---|
CN115531411A (zh) | 2022-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Poinard et al. | Polydopamine coating enhances mucopenetration and cell uptake of nanoparticles | |
Wilson | The transit of dosage forms through the colon | |
CN115531411B (zh) | 一种具备ct成像和治疗双重作用的药物及其制备方法和应用 | |
Hong et al. | Recent advance in colon capsule endoscopy: what’s new | |
JP2018090624A (ja) | 低z原子による腸管ct造影材料 | |
Wang et al. | Gadolinium-loaded solid lipid nanoparticles for colorectal tumor in MR colonography | |
WO2020186804A1 (zh) | 一种胃肠道超声检查助显剂及其制备方法 | |
WO2018113684A1 (zh) | 富勒烯结构在制备治疗白血病的药物中的应用 | |
TWI268780B (en) | Composition for measuring gastric emptying rate | |
CN1217721A (zh) | 治疗或预防间质膀胱炎的方法 | |
CN115487310A (zh) | 一种靶向药物及其制备方法和应用 | |
CN108926579A (zh) | 口服液体益生菌制剂及其制备方法和应用 | |
Hao et al. | PLGA-Au-PFH-NPs-based ultrasound imaging in detecting fetal spinal deformities | |
KR102207507B1 (ko) | 내시경 진단용 염료를 함유하는 고체 경구용 조성물 | |
CN115768431A (zh) | 治疗类风湿性关节炎中的rabeximod | |
RU2666120C1 (ru) | Способ контрастирования толстой кишки при проведении спиральной компьютерной томографии у больных хронической спаечной болезнью брюшины | |
CN1024628C (zh) | 含有植物性食用物的超声显象剂及其制法 | |
CN117065055A (zh) | 一种核壳型纳米酶探针及其制备方法和应用 | |
EP4168021B1 (en) | Fecal matter for treatment of cachexia | |
US20230310335A1 (en) | Nanoparticle containing hydrophobic substance and manufacturing process and use thereof | |
CN113069558B (zh) | 一种可用于类风湿性关节炎的诊疗一体化纳米探针的制备及应用 | |
Lakshmi et al. | Design and evaluation of colon specific drug delivery of naproxen sodium using guar gum and crosslinked guar gum | |
CN116139118A (zh) | 衣康酸及其衍生物在治疗原发性硬化性胆管炎中的应用 | |
CN115137847A (zh) | 共轭碳碘聚合物用于制备胃肠道壁形态检查试剂的应用 | |
Rosario-Berrios et al. | The effect of the size of gold nanoparticle contrast agents on CT imaging of the gastrointestinal tract and inflammatory bowel disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |